Carroll Jason S, Meyer Clifford A, Song Jun, Li Wei, Geistlinger Timothy R, Eeckhoute Jérôme, Brodsky Alexander S, Keeton Erika Krasnickas, Fertuck Kirsten C, Hall Giles F, Wang Qianben, Bekiranov Stefan, Sementchenko Victor, Fox Edward A, Silver Pamela A, Gingeras Thomas R, Liu X Shirley, Brown Myles
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St., Boston, Massachusetts 02115, USA.
Nat Genet. 2006 Nov;38(11):1289-97. doi: 10.1038/ng1901. Epub 2006 Oct 1.
The estrogen receptor is the master transcriptional regulator of breast cancer phenotype and the archetype of a molecular therapeutic target. We mapped all estrogen receptor and RNA polymerase II binding sites on a genome-wide scale, identifying the authentic cis binding sites and target genes, in breast cancer cells. Combining this unique resource with gene expression data demonstrates distinct temporal mechanisms of estrogen-mediated gene regulation, particularly in the case of estrogen-suppressed genes. Furthermore, this resource has allowed the identification of cis-regulatory sites in previously unexplored regions of the genome and the cooperating transcription factors underlying estrogen signaling in breast cancer.
雌激素受体是乳腺癌表型的主要转录调节因子,也是分子治疗靶点的原型。我们在全基因组范围内绘制了所有雌激素受体和RNA聚合酶II的结合位点,确定了乳腺癌细胞中真正的顺式结合位点和靶基因。将这一独特资源与基因表达数据相结合,揭示了雌激素介导的基因调控的不同时间机制,尤其是在雌激素抑制基因的情况下。此外,这一资源还使我们能够在基因组中以前未被探索的区域识别顺式调控位点,以及乳腺癌中雌激素信号传导背后的协同转录因子。